GlassScriptPhysician profile
Amy Doornbos
NPI 1275710386
$3,012.75
in general payments reported to CMS, 2019-2025
30 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.75 · 2022: $238 · 2023: $1,358 · 2024: $889 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253 · Education: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.54 |
| Education | $495.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $434.38 | 2022-2024 | Brukinsa |
| Astellas Pharma US INC | $385.50 | 2023-2025 | Xospata, Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $319.80 | 2023-2025 | |
| Janssen Biotech, INC. | $287.39 | 2022-2024 | Darzalex, Erleada, Akeega |
| Seagen INC. | $182.08 | 2022-2023 | Tukysa, Padcev |
| Eisai INC. | $162.26 | 2023-2024 | |
| Genentech USA, INC. | $126.26 | 2022-2024 | Venclexta |
| Celgene Corporation | $106.97 | 2022-2024 | Reblozyl, Pomalyst |
| Incyte Corporation | $99.99 | 2023 | |
| Merck Sharp & Dohme LLC | $88.62 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Kite Pharma, INC. | $84.64 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $82.63 | 2024-2025 | Lynparza, Calquence |
| Pfizer INC. | $77.24 | 2023-2025 | |
| Genzyme Corporation | $73.95 | 2023-2025 | |
| Glaxosmithkline, LLC. | $69.50 | 2025 | Ojjaara, Blenrep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $67.79 | 2023-2025 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $40.80 | 2023-2025 | Libtayo |
| Daiichi Sankyo INC. | $39.94 | 2022-2023 | Enhertu |
| Mirati Therapeutics, INC. | $33.08 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $32.57 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $32.03 | 2023-2024 | Opdualag |
| Array Biopharma INC | $31.56 | 2023-2024 | Mektovi, Lorbrena, Xalkori |
| Gilead Sciences, INC. | $30.49 | 2023 | Trodelvy |
| Tersera Therapeutics LLC | $22.00 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $19.46 | 2025 | |
| Amgen INC. | $17.64 | 2023 | Kyprolis |
| Exelixis INC. | $16.64 | 2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $16.53 | 2023 | Xpovio |
| Deciphera Pharmaceuticals INC. | $16.43 | 2025 | Qinlock |
| Coherus Oncology, INC. | $14.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Doornbos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.